Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 29 Aug 2025 for iTeos Therapeutics, Inc..
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Matthew Call: trading record in brief
All filings by Matthew Call on record concern iTeos Therapeutics, Inc., in the capacity of senior executive. Between 30 July 2021 and 29 August 2025, the trades on record add up to 5 filings.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The latest filing, published on 29 August 2025, reports a transaction in iTeos Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Matthew Call
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
161,898 sharesCommon StockSEC:0000950170-25-112241:0
24,000 shares0Common StockSEC:0000950170-25-037520:0
44,000 shares0Common StockSEC:0000950170-23-068902:0
40,226 shares@ US$2.9529.1% of flowCommon StockSEC:0001209191-23-021566:0
53,672 shares@ US$2.9554.9% of flowCommon StockSEC:0001209191-21-050063:0
5 of 5 declarations
